| Theme | Liver and Immunology 2019 | |
|---|---|---|
| Title | Current Development Status of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | |
| Publish Date | 2019/05 | |
| Author | Masatoshi Kudo | Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine |
| [ Summary ] | Phase III clinical trials of immune checkpoint inhibitors (IOs) for unresectable hepatocellular carcinoma (HCC) as first‒and second‒line agents are ongoing. Currently trials of adjuvant immunotherapy after curative therapy for HCC including resection or ablation, transarterial chemoembolization (TACE) in combination with IOs, tandem IOs, or IO plus molecular targeted therapy are ongoing. The results of these trials are eagerly awaited. | |